Proof-of-concept for Rapidly Switchable Universal CAR-T Platform with UniCAR-T-CD123 in Relapsed/Refractory AML.

[1]  M. Swayampakula,et al.  Abstract 2176: Using a PSMA-specific low-molecular-weight compound for prostate cancer treatment with rapidly switchable universal CAR-T cells: Overcoming the challenges of cellular immunotherapies in solid tumors , 2020 .

[2]  G. Guyatt,et al.  American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. , 2020, Blood advances.

[3]  J. Esteve,et al.  41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo , 2020, Journal for immunotherapy of cancer.

[4]  S. Jagannath,et al.  Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results. , 2020 .

[5]  S. Jagannath,et al.  Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma. , 2020 .

[6]  M. Swayampakula,et al.  Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia , 2020, Molecular therapy oncolytics.

[7]  S. Gill.  How close are we to CAR T-cell therapy for AML? , 2019, Best practice & research. Clinical haematology.

[8]  K. Kopka,et al.  A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR , 2019, Oncoimmunology.

[9]  M. Bachmann.  The UniCAR system: A modular CAR T cell approach to improve the safety of CAR T cells. , 2019, Immunology letters.

[10]  S. Gill,et al.  Chimeric antigen receptor T-cell therapy for acute myeloid leukemia: how close to reality? , 2019, Haematologica.

[11]  Juliet Investigators.  Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma , 2019 .

[12]  I. Flinn,et al.  Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. , 2019, The Lancet. Oncology.

[13]  C. Turtle,et al.  Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. , 2018, Current research in translational medicine.

[14]  Mithat Gonen,et al.  Long‐Term Follow‐up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia , 2018, The New England journal of medicine.

[15]  Guosheng Yin,et al.  Bayesian optimal interval design for dose finding in drug-combination trials , 2017, Statistical methods in medical research.

[16]  M. Krause,et al.  Characterization of a switchable chimeric antigen receptor platform in a pre-clinical solid tumor model , 2017, Oncoimmunology.

[17]  Bob Löwenberg,et al.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.

[18]  G. Ehninger,et al.  Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts , 2016, Blood Cancer Journal.

[19]  Ying Yuan,et al.  Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials , 2016, Clinical Cancer Research.

[20]  J. Kochenderfer,et al.  Toxicities of chimeric antigen receptor T cells: recognition and management. , 2016, Blood.

[21]  G. Ehninger,et al.  Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia , 2014, Blood Cancer Journal.